Skip to main content
Mohammed Al-Jumayli, MD, Oncology, Tampa, FL, H. Lee Moffitt Cancer Center and Research Institute

MohammedAmeir Abdul KarimAl-JumayliMD

Oncology Tampa, FL

Hematologic Oncology

Assistan professor, Oncology Sciences,USF

Overview of Dr. Al-Jumayli

Dr. Mohammed Al-Jumayli is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from University of Al-Mustansiriyah College of Medicine and has been in practice 18 years. He is one of 172 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. He has more than 20 publications and over 150 citings.

Education & Training

  • Capital Health Regional Medical Center
    Capital Health Regional Medical CenterResidency, Internal Medicine, 2013 - 2016
  • University of Al-Mustansiriyah College of Medicine
    University of Al-Mustansiriyah College of MedicineClass of 1999

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2020 - 2026
  • KS State Medical License
    KS State Medical License 2017 - 2020
  • NJ State Medical License
    NJ State Medical License 2014 - 2018
  • PA State Medical License
    PA State Medical License 2015 - 2015
  • MA State Medical License
    MA State Medical License 2015 - 2015
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Geriatric Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • ASCO Annual Meeting Merit Awards, Conquer Cancer ASCO, Conquer Cancer foundation, 2020

Publications & Presentations

PubMed

Journal Articles

  • Immune Checkpoint Inhibitors versus VEGF Targeted Therapy as Second Line Regimen in Advanced Hepatocellular Carcinoma (HCC): A Retrospective Study  
    A. Saeed, H. Hildebrand, R. Park, M. Al-Jumayli, S. Abbasi, T. Melancon, A. Saeed, R. Al-Rajabi, A. Kasi, J. Baranda, S. Williamson, W. I Sun, Journal of Clinical Medicine, 8/16/2020
  • Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma  
    Robin Park, Fariha Eshrat, Mohammed Al-Jumayli, Azhar Saeed, Anwaar Saeed, Multidisciplinary Digital Publishing Institute, 7/11/2020
  • Association of Serrated polyps with extracolonic malignancies.  
    Mohammed AL-Jumayli,MD,D. Goldsmith, J Rogart,MD, The American Journal of Surgical Pathology
  • Join now to see all

Abstracts/Posters

  • Neoadjuvant cisplatin based therapy in bladder cancer: Is less enough?
    Saqib Abbasi, Mohammed Al-Jumayli, Hannah Hildebrand, Elizabeth Marie Wulff-Burchfield, Eugene K Lee, John A Taylor, Jeffrey Holzbeierlein, Grace Martin, Rahul Atul Pa..., Journal of Clinical Oncology, Chicago,USA, 6/1/2020
  • Clinical Outcomes of different management modalities of Anaplastic Thyroid Cancer: A single Center Experience
    Mohammed Al-Jumayli, Hameem Kawsar, Prakash Neupane, International Journal of Radiation Oncology• Biology• Physics, Arizona, USA, 2/24/2020
  • Immunotherapy versus biologics as second-line therapy in advanced hepatocellular carcinoma (HCC).
    Mohammed Al-Jumayli, Hannah Hildebrand, Saqib Abbasi, Anup Kasi, Anwaar Saeed, American Society of Clinical Oncolog GI , JCO, US, 1/27/2020
  • Join now to see all

Lectures

  • Immunotherapy versus biologics as second-line therapy in advanced hepatocellular carcinoma (HCC). 
    ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020

Hospital Affiliations